ClinicalTrials.gg
Drug

Inaxaplin clinical trials

Also written VX-147.

studies test it
6
open now
0
in phase 3
1
first study started
2020

How each study uses inaxaplin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

IXP
4
Inaxaplin
3

Development codes

VX-147
6

Studies by the year they started

6 studies that test it; most in 2023 (2)

Studies that test inaxaplin, by start year
YearStudies
20201
20221
20232
20241
20251

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
3
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 6 · Other 0

Vertex Pharmaceuticals Incorporated (6)

Studies

Open first, then newest update. How each study uses inaxaplin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 6

Codes

What other systems call inaxaplin · ClinicalTrials.gg INT017846

  • UNII (FDA) S2SJ2RVZ6YINAXAPLINConfirmed FDA, Wikidata
  • Wikidata Q123913944inaxaplinConfirmed FDA, Wikidata
  • NCI Thesaurus C184889InaxaplinOne source FDA
  • DrugBank DB21521One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.